Mazdutide (10mg Vial) Dosage Protocol

Mazdutide (10 mg Vial) Dosage Protocol

Quickstart Highlights

Mazdutide (IBI362) is a long‑acting dual GLP‑1/glucagon receptor agonist developed for chronic weight management and type 2 diabetes.[1][2] Phase 2 and 3 clinical trials have demonstrated substantial weight loss (6–14% reduction over 24–48 weeks) with mostly mild gastrointestinal side effects.[2][3][5] This educational protocol presents a once‑weekly subcutaneous approach with practical dilution for clear insulin‑syringe measurements.

  • Reconstitute: Add 3.0 mL bacteriostatic water → ~3.33 mg/mL concentration (standard protocol).
  • Typical weekly range: 2.5–5 mg once weekly with gradual titration.
  • Easy measuring: At 3.33 mg/mL, 1 unit = 0.01 mL ≈ 33.3 mcg on a U‑100 insulin syringe.
  • Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles.[7]
    • Mazdutide 10mg Vial

    Dosing & Reconstitution Guide

    Educational guide for reconstitution and weekly dosing

    Standard / Gradual Titration (3.0 mL = ~3.33 mg/mL)

    Week Weekly Dose Units (per injection) (mL)
    Weeks 1–4 2.5 mg (2,500 mcg) 75 units (0.75 mL)
    Weeks 5–8+ 5 mg (5,000 mcg) 150 units (1.50 mL)

    Frequency: Inject once weekly subcutaneously. This schedule mirrors clinical trial protocols with gradual titration to improve tolerability.[1][2] The 3.0 mL dilution provides practical unit measurements for standard maintenance doses.

    Reconstitution Steps

  • Draw 3.0 mL bacteriostatic water with a sterile syringe.
  • Inject slowly down the vial wall; avoid foaming.
  • Gently swirl until dissolved (do not shake vigorously).
  • Label with date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.

    • Advanced / High‑Dose Protocol (2.0 mL = 5.0 mg/mL)

    Week Weekly Dose Units (per injection) (mL) Notes
    Weeks 1–4 5 mg (5,000 mcg) 100 units (1.00 mL) 0.5 vials
    Weeks 5–8 7.5 mg (7,500 mcg) 150 units (1.50 mL) 0.75 vials
    Weeks 9–12+ 10 mg (10,000 mcg) 200 units (2.00 mL) 1 vial

    Caution: High‑dose protocols (7.5–10 mg weekly) have been explored in phase 1b research but require careful monitoring and clinical oversight.[1] Doses above 6 mg increase the risk of gastrointestinal side effects. The 2.0 mL reconstitution provides higher concentration to reduce injection volume. For doses requiring >3.0 mL total volume, split into two separate injections at different sites.

    Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

    Supplies Needed

    Plan based on an 8–16 week weekly protocol with gradual titration to 5 mg maintenance.

  • Peptide Vials (Mazdutide, 10 mg each):

    • 8 weeks ≈ 3 vials (Weeks 1–4: 10 mg total = 1 vial; Weeks 5–8: 20 mg total = 2 vials)
    • 12 weeks ≈ 5 vials (Weeks 1–4: 10 mg = 1 vial; Weeks 5–12: 40 mg = 4 vials)
    • 16 weeks ≈ 7 vials (Weeks 1–4: 10 mg = 1 vial; Weeks 5–16: 60 mg = 6 vials)
  • Insulin Syringes (U‑100, 1 mL or 3 mL capacity):

    • Per week: 1 syringe (once‑weekly dosing)
    • 8 weeks: 8 syringes
    • 12 weeks: 12 syringes
    • 16 weeks: 16 syringes
  • Bacteriostatic Water (10 mL bottles): Use 3.0 mL per vial for standard reconstitution.

    • 8 weeks (3 vials): 9 mL → 1 × 10 mL bottle
    • 12 weeks (5 vials): 15 mL → 2 × 10 mL bottles
    • 16 weeks (7 vials): 21 mL → 3 × 10 mL bottles
  • Alcohol Swabs: One for the vial stopper + one for the injection site each week.

    • Per week: 2 swabs
    • 8 weeks: 16 swabs → recommend 1 × 100‑count box
    • 12 weeks: 24 swabs → recommend 1 × 100‑count box
    • 16 weeks: 32 swabs → recommend 1 × 100‑count box
    • Mazdutide 10mg Vial

    View Supplier

    Insulin Syringes

    View Supplier

    Bacteriostatic Water

    View Supplier

    Alcohol Pads

    View Supplier

    Protocol Overview

    Concise summary of the once‑weekly regimen.

  • Goal: Support chronic weight management and metabolic improvement through dual GLP‑1/glucagon receptor activation.[2][3]
  • Schedule: Once‑weekly subcutaneous injections for 8–12 weeks minimum (clinical trials ranged from 12–48 weeks).
  • Dose Range: 2.5–5 mg weekly with gradual titration; advanced protocols may reach 10 mg.
  • Reconstitution: 3.0 mL per 10 mg vial (~3.33 mg/mL) for standard dosing; 2.0 mL for higher concentrations if needed.
  • Storage: Lyophilized frozen at −20 °C (−4 °F); reconstituted refrigerated at 2–8 °C (35.6–46.4 °F); discard after 28 days.[7][9]